Company intelligence / Profile preview

Tissue Regenix

Leeds, England, United Kingdomtissueregenix.com ↗

Ownership: Private
Employees: ~45
Development stage: Commercial

Overview

Tissue Regenix has commercialized several regenerative medical devices based on its proprietary dCELL® and BioRinse™ platforms. These products are used in a variety of surgical specialties and have demonstrated favorable clinical outcomes such as improved healing rates and reduced risk of rejection. The company continues to expand its product portfolio and global reach through direct sales and strategic partnerships

Therapeutic areas: CardiovascularOphthalmologyDermatologyOtherWomen's Health
Modalities: Cell therapyBiologicDevice (biological scaffolds and allografts)Recombinant protein (for decellularized tissue products)
Industry: Surgical Medical Devices

Partnerships

Arthrex Inc. distribution agreementARMS Medical distribution agreement for DermaPure®Premier/Vizient GPO coverage in US hospitals

Beyond the preview

Go deeper on Tissue Regenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tissue Regenix.